本帖最后由 老马 于 2012-1-13 21:20 编辑
% J$ x! H4 `3 s* G" B' _+ o
$ g$ Q4 N8 Y1 f; H爱必妥和阿瓦斯丁的比较
^3 D3 H) K$ Q4 L. C
* F2 Q: k6 {5 H* |4 s
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
) H; x. v6 d% X- n
% Y) o& \% h" P/ e
. L$ Q* I- u) E; R- n0 h& n( d
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
8 B7 K m* V1 H- L8 v" {==================================================0 U, n0 ~: p# z2 h
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), T8 A3 x) L/ f) s' \
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
N9 m. G$ @& ~Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ d1 K: i4 b; k; u
|
显身卡
$ L( m: y7 x7 M2 j5 Y8 u6 n
